Frontlight ResearchEarly access
WithdrawnEarly phase 1
Glucagon-like Peptide-1 in Type 1 Diabetes
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 24 Jun 2020
- Ended
- 24 Sept 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Glucagon-like peptide-1
- Placebos
- Record updated
- 10 November 2025
- Why it stopped
- We were unable to obtain GLP-1
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- 40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr
- HbA1c < 11.0%
- Body mass index < 40kg • m-2
- No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
Who cannot take part
- Subjects taking any of the following medications will be excluded: non-selective beta blockers,
- sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants,
- Subjects on anticoagulant drugs, anemic or with known bleeding diatheses
- Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents
- Hepatic failure /jaundice
- Screening Laboratory Tests Exclusion Criteria
- WBC lower than 3 thou/ul or greater than 14 thou/ul
- Liver function tests: SGOT and SGPT greater than twice upper limit of normal range (i.e. > 80 U/L)
- TBil > 2 mg/dl
- Creatinine > 1.6 mg/dl
- Alkaline phosphatase > 150U/L
- Hepatic transaminase > 2x normal
- Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old
- Subjects unable to give voluntary informed consent
- Pregnancy
- mood stabilizers, CNS stimulants, opioids, hallucinogens
- Subjects unwillingness or inability to comply with approved contraception measures
- Pneumonia
- Abnormal results following screening tests and physical examination that are clinically significant
- Acute cerebrovascular/ neurological deficit
- Fever greater than 38.0 C
- Hematocrit lower than 32
Where in United States
- University of MarylandBaltimore, United States
About the trial
What the trial wants to find out
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
The 3 groups in the trial
- Placebo 1Placebo, for comparison
The participants will be randomized to placebo infusion.
Treatment: Placebos
- Placebo 2Placebo, for comparison
The participants will be randomized to placebo infusion.
Treatment: Placebos
- GLP-1Treatment being tested
The participants will be randomized to Glucagon-like peptide-1 infusion.
Treatment: Glucagon-like peptide-1
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. The Effects of Glucagon-like Peptide-1
- Record updated
- 10 November 2025